Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024
View
Liver Tumours
4
Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024
View
Liver Tumours
4
Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024
View
Liver Tumours
4
Roche: Unveiling the key factors: critical aspects in HCC treatment today - EASL Liver Cancer Summit 2024
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Liver Tumours
5
Roche: Reigniting progress in the HCC treatment landscape - Digital Liver Cancer Summit 2021
View
Metabolism, Alcohol & Toxicity
1
Bristol Myers Squibb: NASH: An evolution in treatment response tools - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
View
Cirrhosis & Complications
4
Shionogi: Raising platelets – the growing evidence supporting the use of TPO-RAs for addressing severe thrombocytopenia prior to invasive procedures in patients with chronic liver disease - ILC 2021
